Understand the source comparison
Can Peptides Help Degenerative Disc Disease: Comparison of Research Compounds
BPC-157 Reduces IL-1β/TNF-α, increases collagen II and aggrecan expression 10–20 μg/kg daily subcutaneous High—multiple disc-specific studies show structural improvement No human clinical trials for disc disease specifically; long-term safety data limited to a
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- BPC-157
- Reduces IL-1β/TNF-α, increases collagen II and aggrecan expression
- 10–20 μg/kg daily subcutaneous
- High—multiple disc-specific studies show structural improvement
- No human clinical trials for disc disease specifically; long-term safety data limited to animal models
- TB-500
- Promotes actin polymerisation, enhances endplate nutrient diffusion, supports angiogenesis in vertebral bone
- 500–750 μg twice weekly
- Moderate—demonstrated efficacy in annular tear models but fewer disc-specific studies than BPC-157
- Mechanism requires sustained administration; effects plateau after 8–12 weeks
- MK 677
- Elevates systemic IGF-1, indirect cartilage anabolic support
- 12.5–25 mg oral daily
- Low for disc-specific outcomes—strong evidence for IGF-1 elevation but no direct disc regeneration trials
- Systemic effects (water retention, increased appetite) may complicate use; indirect mechanism vs targeted action
- Thymalin
- Immune modulation, reduces chronic inflammation markers
- 5–10 mg intramuscular 2x/week
- Low—supportive role in reducing systemic inflammation but no disc-specific trials
- Mechanism addresses downstream inflammation, not primary degenerative drivers
- GHK-Cu
- Stimulates fibroblast activity, collagen synthesis, tissue remodelling
- 1–3 mg subcutaneous 3x/week
- Low—general wound healing evidence but minimal disc-specific research
- Copper toxicity concerns at higher doses; requires careful sourcing for purity